You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study

 

Online download statistics by month:

Online download statistics by month: November 2020 to August 2025

AbstractFullPdf
Nov 2020378380191
Dec 202022322395
Jan 202111111148
Feb 202110710739
Mar 202118918957
Apr 2021919146
May 2021949438
Jun 2021787843
Jul 2021848441
Aug 2021696938
Sep 2021797952
Oct 2021838367
Nov 202111011397
Dec 2021808454
Jan 2022707340
Feb 2022777842
Mar 202214014264
Apr 202211912347
May 2022838751
Jun 20228910243
Jul 2022656736
Aug 2022676837
Sep 2022676736
Oct 2022909569
Nov 2022828449
Dec 2022727237
Jan 2023414134
Feb 202311411445
Mar 2023636445
Apr 2023454533
May 2023464635
Jun 2023454732
Jul 2023353533
Aug 2023606120
Sep 2023606136
Oct 2023626223
Nov 202310210238
Dec 202323123138
Jan 2024868771
Feb 2024636335
Mar 2024105107129
Apr 2024878758
May 2024869165
Jun 2024727144
Jul 2024717432
Aug 2024626321
Sep 2024596147
Oct 2024979947
Nov 202410010143
Dec 202411611766
Jan 2025858686
Feb 2025595947
Mar 2025727266
Apr 202510610672
May 2025777782
Jun 2025414136
Jul 2025110
Aug 2025110
Total514752162916